Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma
Anthracyclines have a central role in the management of non-Hodgkin’s lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2011-10-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/3868 |
| _version_ | 1828046550623846400 |
|---|---|
| author | Dino Amadori |
| author_facet | Dino Amadori |
| author_sort | Dino Amadori |
| collection | DOAJ |
| description | Anthracyclines have a central role in the management of non-Hodgkin’s lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.<br /> |
| first_indexed | 2024-04-10T18:27:21Z |
| format | Article |
| id | doaj.art-10405c928837427395681309322af20a |
| institution | Directory Open Access Journal |
| issn | 2038-8322 2038-8330 |
| language | English |
| last_indexed | 2024-04-10T18:27:21Z |
| publishDate | 2011-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-10405c928837427395681309322af20a2023-02-02T04:57:05ZengMDPI AGHematology Reports2038-83222038-83302011-10-0133se1e110.4081/hr.2011.s3.e11759Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphomaDino Amadori0Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), MeldolaAnthracyclines have a central role in the management of non-Hodgkin’s lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.<br />http://www.pagepress.org/journals/index.php/hr/article/view/3868anthracycline, non-Hodgkin’s lymphoma, doxorubicin, liposomal doxorubicin |
| spellingShingle | Dino Amadori Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma Hematology Reports anthracycline, non-Hodgkin’s lymphoma, doxorubicin, liposomal doxorubicin |
| title | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma |
| title_full | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma |
| title_fullStr | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma |
| title_full_unstemmed | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma |
| title_short | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin’s lymphoma |
| title_sort | moving forward with new data and approaches a fresh look at anthracyclines in non hodgkin s lymphoma |
| topic | anthracycline, non-Hodgkin’s lymphoma, doxorubicin, liposomal doxorubicin |
| url | http://www.pagepress.org/journals/index.php/hr/article/view/3868 |
| work_keys_str_mv | AT dinoamadori movingforwardwithnewdataandapproachesafreshlookatanthracyclinesinnonhodgkinslymphoma |